
Sheet 1 of 33

FORM PTO-1449 (REV. 7-85) U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION



ATTY. DOCALT NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER		AME					
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SL/	AA	4,444,887	4/24/84	Hoffmann			
1	AB	4,474,893	10/2/84	Reading			/
	AC	4,631,211	12/23/86	Houghten			
	AD	4,676,980	6/30/87	Segal et al.			
	AE	4,714,681	12/22/87	Reading			7
	AF	4,716,111	12/29/87	Osband et al.			7
	AG	4,741,900	5/3/88	Alvarez et al.			/
1	AH	4,816,397	3/28/89	Boss et al.			
	Al	4,816,567	3/28/89	Cabilly et al.			
1	AJ	4,925,648	5/15/90	Hansen et al.		X	
1	AK	4,946,778	8/7/90	Ladner et al.		171	
1	AL	5,010,175	4/23/91	Rutter et al.		// /	<i></i>
		· · · · · · · · · · · · · · · · · · ·	FOREIG	N PATENT DOCUMENTS		/	DAVISI AZION
		DOCUMENT NUMBER	DATE	OFFICE	CLASS S	UBCLASS T	RANSLATION ES NO
	AM	EP 0 171 496	5/26/93	EP ·	.1 /		3 \ _
	- Alvi	EP 0 17 1 490					- \
	AN	EP 0 171 496	3/5/86	EP .			
		 	3/5/86 8/3/94	EP EP			
	AN	EP 0 173 494					
	AN AO	EP 0 173 494 EP 0 239 400	8/3/94	EP			
	AN AO AP	EP 0 173 494 EP 0 239 400 EP 0 307 434 EP 0 322 094	8/3/94 7/29/98 12/2/92	EP EP	nent pages, Etc.		
	AN AO AP	EP 0 173 494 EP 0 239 400 EP 0 307 434 EP 0 322 094 OTHER DOC	8/3/94 7/29/98 12/2/92 UMENTS (Distinct type	EP EP Including Author, Title, Date, Pertings of diffuse large B-cell lymph			
	AN AO AP AQ	EP 0 173 494 EP 0 239 400 EP 0 307 434 EP 0 322 094 OTHER DOC Alizadeh, A.A. et al., "profiling", Nature, Vol.	8/3/94 7/29/98 12/2/92 UMENTS (Distinct type 403, pp. 50	EP EP Including Author, Title, Date, Pertings of diffuse large B-cell lymph	oma identified	bhage display	pression
	AN AO AP AQ	EP 0 173 494 EP 0 239 400 EP 0 307 434 EP 0 322 094 OTHER DOC Alizadeh, A.A. et al., "profiling", Nature, Vol. Ames, R.S. et al., "Cofull length immunoglo! Arnon, R. et al., "Mon	8/3/94 7/29/98 12/2/92 UMENTS (Distinct type 403, pp. 50 Inversion of bulins", Jour	EP EP Including Author, Title, Date, Pertines of diffuse large B-cell lymph 3-511 (2000) murine Fabs isolated from a c	oma identified ombinatorial p s, Vol. 184, pp Drugs in Can	bhage display, 177-186 (19	pression library to

Sheet 2 of 33

FORM PTO-1449 (REV. 7-85)

MENT OF COMMERCE U.S. DE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

			Ų.S. F	ATENT DOCUMENTS			
AMINER NITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
7SL/	2AA	5,112,946	5/12/92	Maione			
1	2AB	5,122,464	6/16/92	Wilson et al.			
	2AC	5,223,409	6/29/93	Ladner et al.			
	2AD	5,225,539	7/6/93	Winter			
	2AE	5,258,498	11/2/93	Huston et al.	. \		/
	2AF	5,288,514	2/22/94	Ellman			/
	2AG	5,314,995	5/24/94	Fell, Jr. et al.			
	2AH	5,336,603	8/9/94	Capon et al.		\setminus	
	2AI	5,349,053	9/20/94	Landolfi			
	2AJ	5,359,046	10/25/94	Capon et al.		X	
	2AK	5,403,484	4/4/95	Ladner et al.			
	2AL	5,413,923	5/9/95	Kucherlapati et al.			
			FOREIG	N PATENT DOCUMENTS		' \	•
		DOCUMENT NUMBER	DATE	OFFICE	CLASS SUE	CLASS TRA	NSLATIC
	2AM	EP 0 367 166	5/9/90	EP			
	2AN	EP 0 394 827	10/31/90	EP			7
	2AO	EP 0 396 387	12/22/93	EP			
	2AP	EP 0 413 622	2/11/98	EP			
	2AQ	EP 0 439 095	5/20/98	EP			
		OTHER DOC	UMENTS (Including Author, Title, Date, Pe	rtinent pages, Etc.)		
	2AR	Ashkenazi, A. et al., "I immunoadhesin", Pro	Protection ago. Natl. Acad	gainst endotoxic shock by a 1. Sci. USA, Vol. 88, pp. 105	tumor necrosis fa 535-10539 (1991)	ctor receptor	
	2AS	Ausubel, F.M. et al., e Sons, Inc., publ., pp.	ds., Current I-11 (table o	Protocols in Molecular Biolof f contents) (2001)	ogy, Vols. 1, 2, 3 a	and 4, John V	Viley &
丁	2AT	Ausubel, F.M. et al., e Molecular Biology, Vo	ds., Unit 2.1 I. 1, John W	0: "Hybridization Analysis of the Sons, Inc., publ., pp.	of DNA Blots", Cui 2.10.1-2.10.16 (19	rent Protoco 993)	ls in
Y	1						

MENT OF COMMERCE PATENT AND TRADEMARK OFFICE **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Sheet 3 of 33

Group

			U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
SL/	3AA	5,427,908	6/27/95	Dower et al.	N N		
1	3AB	5,447,851	9/5/95	Beutler et al.			
	3AC	5,474,981	12/12/95	Leder et al.			7
	3AD	5,506,337	4/9/96	Summerton et al.			7
	3AE	5,516,637	5/14/96	Huang et al.			7
	3AF	5,519,134	5/21/96	Acevedo et al.			/
	3AG	5,525,735	6/11/96	Gallop et al.			
	ЗАН	5,530,101	6/25/96	Queen et al.			
	3AI	5,539,083	7/23/96	Cook et al.			
	3AJ	5,545,806	8/13/96	Lonberg et al.			
	3AK	5,549,974	8/27/96	Holmes			
	3AL	5,565,332	10/15/96	Hoogenboom et al.			
			FOREIG	N PATENT DOCUMENTS			
†		DOCUMENT NUMBER	DATE	OFFICE	CLASS SUB	CLASS TRA	NSLATIOI NO
	ЗАМ	EP 0 519 596	12/23/92	EP	. /		$\nabla \Box$
	3AN	EP 0 592 106	4/13/94	EP			
	3AO	WO 86/01533	3/13/86	PCT			T
	3AP	WO 86/05807	10/9/86	PCT			
	3AQ	WO 87/02671	5/7/87	PCT	1		
		OTHER DOC	UMENTS (Including Author, Title, Date, Per	rtinent pages, Etc.)		·
	3AR			: "Using DNA Fragments as ley & Sons, Inc., publ., pp. 6		Protocols in	
	<u>† </u>			8: "Immunoblotting and Imriley & Sons, Inc., publ., pp. "			ols in
	3AS]					
\\	3AS 3AT	Ausubel, F.M. et al., e		16: "Immunoprecipitation", abl., pp. 10.16.1-10.16.29 (1		in Molecular	Biology,

FORM PTO-1449

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE

Sheet 4 of 33

JULY 9, 2004

Group

(REV. 7-85) **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

				PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS	S SUBCL	ASS	FILING DATE
SL/	4AA	5,569,588	10/29/96	Ashby et al.	\			
	4AB	5,569,825	10/29/96	Lonberg et al.	1			
	4AC	5,571,698	11/5/96	Ladner et al.	. \			7
	4AD	5,573,920	11/12/96	Randle				\mathcal{I}
	4AE	5,580,717	12/3/96	Dower et al.	•			
	4AF	5,585,089	12/17/96	Queen et al.				
	4AG	5,593,853	1/14/97	Chen et al.				
	4AH	5,601,819	2/11/97	Wong et al.				
	4AI	5,605,793	2/25/97	Stemmer				
	4AJ	5,622,929	4/22/97	Willner et al.				
	4AK	5,625,126	4/29/97	Lonberg et al.				
	4AL	5,633,425	5/27/97	Lonberg et al.		y		
	•		FOREIG	N PATENT DOCUMENTS			\	
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAI YES	SLATIO
	4AM	WO 87/04462	7/30/87	PCT				P
	4AN	WO 89/01036	2/9/89	PCT				
	4AO	WO 89/10404	11/2/89	PCT				
	4AP	WO 89/12624	12/28/89	PCT				
	4AQ	WO 90/02809	3/22/90	PCT	/			
		OTHER DOC	UMENTS (Including Author, Title, Date, Pe	/ rtinent pages, Et	c.)		
	4AR	Ausubel, F.M. et al., e Protocols in Molecula	ds., Unit 11. r Biology, Vo	2: "Enzyme-Linked Immunol. 2, John Wiley & Sons, Inc	osorbent Assa ., publ., pp. 1	ys (ELISA)" I.2.1-11.2.2	, Curr 2 (199	ent 91)
	4AS	(1993)	•	of benzodiazepines", Chem				_
	4AT	Bebbington, C.R. et a	l., "High-Lev se Gene as	el Expression of a Recombi an Amplifiable Selectable M	nant Antibody larker". Bio/Te	from Myelo chnology, V	ma Ce ol. 10	ells Usir

Sheet 5 of 33

FORM PTO-1449 (REV. 7-85) U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

			U.S. F	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/SL/	5AA	5,652,361	7/29/97	Simon et al.			
1	5AB	5,658,727	8/19/97	Barbas et al.			
	5AC	5,661,016	8/26/97	Lonberg et al.			
	5AD	5,698,426	12/16/97	Huse			
	5AE	5,733,743	3/31/98	Johnson et al.			
	5AF	5,750,753	5/12/98	Kimae et al.			
	5AG	5,756,065	5/26/98	Wilson et al.			
	5AH	5,766,883	6/16/98	Ballance et al.			
•	5AI	5,780,225	7/14/98	Wigler et al.		\	
	5AJ	5,807,715	9/15/98	Morrison et al.		V	
	5AK	5,811,238	9/22/98	Stemmer et al.			
	5AL	5,814,318	9/29/98	Lonberg et al.			
			FOREIG	N PATENT DOCUMENTS		/ \	
		DOCUMENT NUMBER	DATE	OFFICE	CLASS 9	JBCLASS TRA	NSLATION NO
	5AM	WO 91/00360 ·	1/10/91	PCT			
	5AN	WO 91/06570	5/16/91	PCT			7
	5AO	WO 91/06657	5/16/91	PCT			□ / ·
	5AP	WO 91/09967	7/11/91	PCT			
	5AQ	WO 91/10737	7/25/91	PCT			
	•	OTHER DOC	UMENTS (Including Author, Title, Date, Perti	nent pages, Etc.)	• .	
	5AR	Chimera of its Recepto Interaction Biosensor A	r α Subunit a \nalysis", Jou	rization of the Interaction of Bio and Development of an ELISA S urnal of Molecular Recognition,	Screening Assa Vol. 8, pp. 52-5	y using Real-Tir 8 (1995)	ne
	5AS	Better, M. et al., " <i>Escl</i> 240, pp. 1041-1043 (1	herichia coli 1988)	Secretion of an Active Chimer	ric Antibody Fr	agment", Scier	
$\overline{\downarrow}$	5AT	Bibila, T.A. et al., "In F Biotechnol. Prog., Vol		e Optimal Fed-Batch Process pp. 1-13 (1995)	for Monociona	I Antibody Prod	duction",
EXAMI	NER	/Sue/Liu/	· · · · · · · · · · · · · · · · · · ·	DATE CONSIDERED	11/06/200	7	

MENT OF COMMERCE **FORM PTO-1449** U.S. DE PATENT AND TRADEMARK OFFICE (REV. 7-85)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY, DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. FILING DATE JULY 9, 2004

Group

Sheet 6 of 33

U.S. PATENT DOCUMENTS CLASS SUBCLASS NAME **DOCUMENT NUMBER** DATE /SL/ 10/13/98 Garrard et al. 6AA 5.821.047 11/3/98 Stemmer et al. 6AB 5,830,721 11/10/98 Stemmer et al. 6AC 5.834.252 Minshull et al. 6AD 5,837,458 11/17/98 6AE 3/2/99 Fleer et al. 5,876,969 3/23/99 Griffiths et al. 6AF 5,885,793 6/29/99 Hori et al. 6AG 5,916,771 8/17/99 Kucherlapati et al. 6AH 5,939,598 5,969,108 McCafferty et al. 10/19/99 6AI 6AJ 5.985.660 11/16/99 Galy 2/1/00 Pantoliano et al. 6AK 6,020,141 6AL 6,036,920 3/14/00 Pantoliano et al. FOREIGN PATENT DOCUMENTS TRANSLATION YES NO **CLASS SUBCLASS DOCUMENT NUMBER** DATE **OFFICE PCT** 7/25/91 6AM WO 91/10741 WO 91/14438 10/3/91 PCT 6AN 12/26/91 **PCT** 6AO WO 91/19735 1/9/92 **PCT** 6AP WO 92/00091 1/23/92 **PCT** 6AQ WO 92/01047 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Bitter, G.A. et al., "Expression and Secretion Vectors for Yeast", Methods in Enzymology, Vol. 153, pp. 516-544 (1987) 6AR Bittner, M. et al., "Molecular classification of cutaneous malignant melanoma by gene expression profiling", Nature, Vol. 406, pp. 536-540 (2000) 6AS Blanchard, A.P. et al., "Sequence to array: Probing the genome's secrets", Nature Biotechnology, Vol. 14, pp. 1649-1651 (1996) 6AT DATE CONSIDERED **EXAMINER** 11/06/2007

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in *EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.

/Sue Liu/

U.S. DE MENT OF COMMERCE

ATTY. DOC **D0185 US PCT** APPLICATION NO. HUANG ET AL.

Sheet 7 of 33

FILING DATE

JULY 9, 2004

Group

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION 10/501,035 (Use several sheets if necessary) APPLICANT

U.S. PATENT DOCUMENTS SUBCLASS FILING CLASS **DOCUMENT NUMBER** DATE /SL/ 7AA 6,075,181 6/13/00 Kucherlapati et al. 7AB 9/5/00 6,114,598 Kucherlapati et al. AC AD AE AF AG AH ΑI ΆJ **FOREIGN PATENT DOCUMENTS** TRANSLATION YES NO **OFFICE** CLASS **SUBCLASS DOCUMENT NUMBER** DATE 4/16/92 PCT 7AM WO 92/05793 7AN WO 92/08495 5/29/92 **PCT 7AO** WO 92/08802 5/29/92 **PCT** 7AP WO 92/18619 10/29/92 PCT WO 92/22324 12/23/92 PCT 7AQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Blume-Jensen, P. et al., "Oncogenic kinase signalling", Nature, Vol. 411, pp. 355-365 (2001). 7AR Boulianne, G.L. et al., "Production of functional chimaeric mouse/human antibody", Nature, Vol. 312, pp. 643-646 (1984) 7AS Brinkmann, U. et al., "Phage display of disulfide-stabilized Fv fragments", Journal of Immunological Methods, Vol. 182, pp. 41-50 (1995) 7AT DATE CONSIDERED **EXAMINER** 11/06/2007 /Sue Liu/

Sheet 8 of 33

FORM PTO-1449 (REV. 7-85)

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY, DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

FOREIGN PATENT DOCUMENTS

			I OILLIO	NI ATENI BOOOMENTO		·	
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION YES NO
	8AA	WO 93/11236	6/10/93	PCT	·		
1	8AB	WO 93/17715	9/16/93	PCT			
	8AC	WO 93/20242	10/14/93	PCT			
	8AD	WO 93/21232	10/28/93	PCT			
	8AE	WO 95/15982	6/15/95	PCT			
	8AF	WO 95/20401	8/3/95	PCT			
	8AG	WO 96/04388	2/15/96	PCT			
	8AH	WO 96/22024	7/25/96 .	PCT			
	8AI	WO 96/33735	10/31/96	PCT			
	8AJ	WO 96/34096	10/31/96	PCT			
	8AK	WO 97/00271	1/3/97	PCT			d
	8AL	WO 97/46251	12/11/97	PCT			
	8AM	WO 98/16654	4/23/98	PCT			
	8AN	WO 98/24893	6/11/98	PCT		\setminus	
	8AO	WO 98/46645	10/22/98	PCT			
	8AP	WO 98/50433	11/12/98	PCT .			
	8AQ	WO 99/04813	2/4/99	PCT	4		
∇	8AR	WO 00/62778	10/26/00	PCT			
	AS					. /	
	AI						
	AU						
	Α̈́V	X					
	AW						
	AX						
	AY						
-	AZ						
EXAM	INER	/Sue Liu/		DATE CONSIDERED	11/06/2	2007	

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT

HUANG ET AL. **FILING DATE** JULY 9, 2004

Group

Sheet 9 of 33

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		OTTIER BOODINETTIO (morading	A Marion, 1110, 5410, 1 Orthorn pages, 210.
/SL/	9AA	Brown, M.T. et al., "Regulation, substra Vol. 1287, pp. 121-149 (1996)	tes and functions of src", Biochimica et Biophysica Acta,
	9AB	Burton, D.R. et al., "Human Antibodies Vol. 57, pp. 191-280 (1994)	from Combinatorial Libraries", Advances in Immunology,
	9AC	Repeat T Cell Epitopes of the Circums Immunology, Vol. 150, No. 4, pp. 1403	
	9AD	Campbell, D.A. et al., "Phosphonate Es J. Org. Chem., Vol. 59, No. 3, pp. 658-	ster Synthesis Using a Modified Mitsunobu Condensation", 660 (1994)
	9AE	Combinatorial Chemistry in Small-Mole 2661-2662 (1994)	Synthesis of Small-Compound Libraries: Validation of cule Synthesis", J. Am. Chem. Soc., Vol. 116, No. 6, pp.
	9AF	Chen, SY. et al., "Intracellular Antiboo Therapy", Human Gene Therapy, Vol.	lies as a New Class of Therapeutic Molecules for Gene 5, pp. 595-601 (1994)
	9AG	Cho, C.Y. et al., "An Unnatural Biopoly	mer", Science, Vol. 261, pp. 1303-1305 (1993)
	9AH	Chothia, C. et al., "Canonical Structure Mol. Biol., Vol. 196, pp. 901-917 (1987	s for the Hypervariable Regions of Immunoglobulins", J.)
	9AI	Chothia, C. et al., "Conformations of im 877-883 (1989)	nmunoglobulin hypervariable regions", Nature, Vol. 342, pp.
1	9AJ	Chothia, C. et al., "Structural Determin- J. Mol. Biol., Vol. 278, pp. 457-479 (19	ants in the Sequences of Immunoglobulin Variable Domain", 98)
	9AK	Chow, M. et al., "Synthetic peptides from protein VP1 induce neutralizing antibode (1985)	om four separate regions of the poliovirus type 1 capsid dies", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 910-914
	9AL		integration of the technology within pharmaceutical research Biotechnology, Vol. 11, pp. 602-609 (2000)
1	9AM	Hamster Ovary Cells Using Glutamine 662-667 (1990)	sion of Tissue Inhibitor of Metalloproteinases in Chinese Synthetase Gene Amplification", Bio/Technology, Vol. 8, pp.
$\sqrt{}$	9AN	Cohen, P.A. et al., "Characterization of human p53", Oncogene, Vol. 17, pp. 2	f a new intrabody directed against the N-terminal region of 445-2456 (1998)
EXAM	INER	/Sue Liu/	DATE CONSIDERED 11/06/2007
			the MOCO COO. Deare a line through eiteding if not in

MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DO **D0185 US PCT** APPLICATION NO. 10/501,035 **APPLICANT**

Sheet 10 of 33

HUANG ET AL. FILING DATE

JULY 9, 2004

Group

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	10AA	Colbère-Garapin, F. et al., "A New Dor J. Mol. Biol., Vol. 150, pp. 1-14 (1981)	minant Hybrid Selective Marker for Higher Eukaryotic Cells",
	10AB		ma Technique and Its Application to Human Lung Cancer", erapy, Alan R. Liss, Inc., publ., Reisfeld, R.A. et al., eds., pp.
	10AC	Coligan, J.E. et al., eds., Unit 7.22: "G	Generation of Epstein-Barr Virus (EBV) – Immortalized B Cell gy, Vol. 1, John Wiley & Sons, Inc., publ., pp. 7.22.1-7.22.3
	10AD		mplification of Engineered Mouse Dihydrofolate Reductase blogy, Vol. 3, No. 2, pp. 257-266 (1983)
	10AE	DeNardo, G.L. et al., "Comparison of 1,4,7,10-T a Novel Immunoconjugate with Catabolizable Li Breast Cancer Xenografts", Clinical Cancer Res	etraazacyclododecane- <i>N,N',N'', N'''</i> -tetraacetic acid (DOTA)-Peptide-ChL6, nker, to 2-Imlnothiolane-2-[p-(Bromoacetamido)benzyl]-DOTA-ChL6 in search, Vol. 4, pp. 2483-2490 (1998)
	10AF	DeWitt, S.H. et al., "'Diversomers': Al Proc. Natl. Acad. Sci. USA, Vol. 90, pp	n approach to nonpeptide, nonoligomeric chemical diversity", p. 6909-6913 (1993)
	10AG	Dracapoli, N.C. et al., eds., Chapter 12 Genetics, Vol. 3, John Wiley & Sons, I	2: "Vectors for Gene Therapy", Current Protocols in Human nc., publ., pp. 12.0.1-12.12.15 (1999)
	10AH		3: "Delivery Systems for Gene Therapy", Current Protocols & Sons, Inc., publ., pp. 13.0.1-13.10.7 (1999)
	10AI	Du Pasquier, L., Chapter 7: "Evolution Edition, Raven Press Ltd., publ., Paul,	n of the Immune System", Fundamental Immunology, Second W.E., ed., pp. 139-165 (1989)
	10AJ		and Characterization of a Fusion Protein Consisting of a reinomas and Human IL-2", The Journal of Immunology, Vol.
	10AK	Foecking, M.K. et al., "Powerful and vectors", Gene, Vol. 45, pp. 101-105 (ersatile enhancer-promoter unit for mammalian expression 1986)
	10AL	Fountoulakis, M. et al., "Interferon γ R. Protein in Chinese Hamster Ovary Ce 3958-3964 (1995)	eceptor Extracellular Domain Expressed as IgG Fusion lls", The Journal of Biological Chemistry, Vol. 270, No. 8, pp.
	10AM	Francis, M.J. et al., "Immunological Pr Virus", J. Gen. Virol., Vol. 66, pp. 234	iming with Synthetic Peptides of Foot-and-Mouth Disease 7-2354 (1985)
$\overline{\mathbf{V}}$	10AN	Freeman, W.M. et al., "Fundamentals BioTechniques, Vol. 29, No. 5, pp. 10-	of DNA Hybridization Arrays for Gene Expression Analysis", 42-1055 (2000)
EXAMI	NER	· /Sue Liu/	DATE CONSIDERED 11/06/2007

Sheet 11 of 33

FORM PTO-1449 U.S. (REV. 7-85) PAT

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOGNET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	11AA	Furka, A. et al., "General method for rapid synthesis of multicomponent peptide mixtures", Int. J. Peptide Protein Res., Vol. 37, pp. 487-493 (1991)
	11AB	Gentz, R. et al., "Bioassay for trans-activation using purified human immunodeficiency virus tatencoded protein: Trans-activation requires mRNA synthesis", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 821-824 (1989)
	11AC	Geysen, H.M. et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid", Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 3998-4002 (1984)
	11AD	Gillies, S.D. et al., "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 1428-1432 (1992)
	11AE	Gillies, S.D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes", Journal of Immunological Methods, Vol. 125, pp. 191-202 (1989)
	11AF	Goldspiel, B.R. et al., "Human Gene Therapy", Clinical Pharmacy, Vol. 12, pp. 488-505 (1993)
	11AG	Golub, T.R. et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, Vol. 286, pp. 531-537 (1999)
	11AH	Green, L.L., "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", Journal of Immunological Methods, Vol. 231, pp. 11-23 (1999)
	11Al	Green, L.L. et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs", Nature Genetics, Vol. 7, pp. 13-21 (1994)
	11AJ	Green, L.L. et al., "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes", J. Exp. Med., Vol. 188, No. 3, pp. 483-495 (1998)
	11AK	Greenspan, N.S. et al., "Idiotypes: structure and immunogenicity", The FASEB Journal, Vol. 7, pp. 437-444 (1993)
	11AL	Hagihara, M. et al., "Vinylogous Polypeptides: An Alternative Peptide Backbone", J. Am. Chem. Soc., Vol. 114, No. 16, pp. 6568-6570 (1992)
	11AM	Hämmerling, G.J. et al., eds., "Production of Antibody-Producing Hybridomas in the Rodent Systems", Monoclonal Antibodies and T-Cell Hybridomas: Perspectives and technical advances, Elsevier/North-Holland Biomedical Press, publ., pp. 563-587 (1981)
$\sqrt{}$	11AN	Hansson, L.O. et al., "Evolution of Differential Substrate Specificities in Mu Class Glutathione Transferases Probed by DNA Shuffling", J. Mol. Biol., Vol. 287, pp. 265-276 (1999)
EXAMI	NER	Sue Liu/ DATE CONSIDERED 11/06/2007

FORM PTO-1449
(REV. 7-85)
U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCRET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

EXAMI	NER	/Sue Liu/	DATE CONSIDERED 11/06/2007
\bigvee	12AN		gnostic prediction of cancers using gene expression profiling Medicine, Vol. 7, No. 6, pp. 673-679 (2001)
	12AM	using phage-antibody libraries and the fragments", Eur. J. Immunol., Vol. 24,	
	12AL	Johanson, K. et al., "Binding Interaction Journal of Biological Chemistry, Vol. 2	ons of Human Interleukin 5 with Its Receptor α Subunit", The 170, No. 16, pp. 9459-9471 (1995)
	12AK	Jespers, L.S. et al., "Guiding the Selection a Single Epitope of an Antigen", Bio/T	ction of Human Antibodies from Phage Display Repertoires t echnology, Vol. 12, pp. 899-903 (1994)
	12AJ	Janknecht, R. et al., "Rapid and efficie recombinant vaccinia virus", Proc. Nat	ent purification of native histidine-tagged protein expressed b d. Acad. Sci. USA, Vol. 88, pp. 8972-8976 (1991)
	12AI	Inouye, S. et al., "Up-prompter mutation Research, Vol. 13, No. 9, pp. 3101-31	ons in the <i>lpp</i> gene of <i>Escherichia coli</i> ', Nucleic Acids 09 (1985)
	12AH	Huston, J.S. et al., "Protein Engineerir in Enzymology, Vol. 203, pp. 46-88 (19	ng of Single-Chain Fv [.] Analogs and Fusion Proteins", Method 1991)
	12AG	research and drug discovery", Nature,	
	12AF	Specificity of antigen-antibody interact Sci. USA, Vol. 82, pp. 5131-5135 (198	
	12AE	Holliger, P. et al., " 'Diabodies': Small Acad. Sci. USA, Vol. 90, pp. 6444-644	bivalent and bispecific antibody fragments", Proc. Natl. 8 (1993)
	12AD	Somatostatin Agonist Bearing a Close Antagonist", J. Am. Chem. Soc., Vol. 1	ptidomimetics with a β-D-Glucose Scaffolding. A Partial Structural Relationship to a Potent, Selective Substance P 14, pp. 9217-9218 (1992)
	12AC	Fundamentals and Applications, Seconds., pp. 623-653 (1987)	tibodies for Drug Delivery", Controlled Drug Delivery: nd Edition, Marcel Dekker, Inc., publ., Robinson, J.R. et al.,
	12AB	Harlow, E. et al., Antibodies: A Labora (table of contents) (1988)	tory Manual, Cold Spring Harbor Laboratory, publ., pp. iii-ix
/SL/	12AA	Harayama, S., "Artificial evolution by D	NA shuffling", TIBTECH, Vol. 16, pp. 76-82 (1998)

FORM PTO-1449 U.S. DE MENT OF COMMERCE (REV. 7-85) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY, DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

Sheet 13 of 33

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	13AA	Khan, J. et al., "Gene Expression Prof Microarrays", Cancer Research, Vol. 5	iling of Alveolar Rhabdomyosarcoma with cDNA 58, pp. 5009-5013 (1998)
	13AB	Köhler, G., "Immunoglobulin chain los No. 4, pp. 2197-2199 (1980)	s in hybridoma lines", Proc. Natl. Acad. Sci. USA, Vol. 77,
	13AC	Köhler, G. et al., "Continuous cultures Nature, Vol. 256, pp. 495-497 (1975)	of fused cells secreting antibody of predefined specificity",
	13AD	Kostelny, S.A. et al., "Formation of a E Journal of Immunology, Vol. 148, No.	Sispecific Antibody by the Use of Leucine Zippers", The 5, pp. 1547-1553 (1992)
	13AE	Kozbor, D. et al., "The production of m Today, Vol. 4, No. 3, pp. 72-79 (1983)	nonoclonal antibodies from human lymphocytes", Immunology
	13AF	Kriegler, M., Gene Transfer and Expre (table of contents) (1990)	ession: A Laboratory Manual, Stockton Press, publ., pp. vii-x
	13AG	Kütemeier, G. et al., "Assembly of Hui Using a Single-Round PCR", BioTech	manized Antibody Genes from Synthetic Oligonucleotides niques, Vol. 17, No. 2, pp. 242-246 (1994)
	13AH	Liang, R. et al., "Parallel Synthesis an Science, Vol. 274, pp. 1520-1522 (199	d Screening of a Solid Phase Carbohydrate Library", 96)
	13Al	Lockhart, D.J. et al., "Expression mon arrays", Nature Biotechnology, Vol. 14	itoring by hybridization to high-density oligonucleotide I, pp. 1675-1680 (1996)
	13AJ	Logan, J. et al., "Adenovirus tripartite infection", Proc. Natl. Acad. Sci. USA,	leader sequence enhances translation of mRNAs late after Vol. 81, pp. 3655-3659 (1984)
 	13AK		Method for the Introduction of Mutations in Genes Cloned and Inniques, Vol. 24, No. 2, pp. 308-313 (1998)
•	13AL	Lowy, I. et al., "Isolation of Transform 817-823 (1980)	ing DNA: Cloning the Hamster aprt Gene", Cell, Vol. 22, pp.
	13AM	Marasco, W.A., "Intrabodies: turning immunization", Gene Therapy, Vol. 4,	the humoral immune system outside in for intracellular pp. 11-15 (1997)
V-	13AN		plant of megabase human immunoglobulin loci recapitulates ature Genetics, Vol. 15, pp. 146-156 (1997)
EXAM	INER	/Sue Liu/	DATE CONSIDERED 11/06/2007
.=>			is annual and the MADED COO. Draw a line through attains if not in

FORM PTO-1449
(REV. 7-85)
U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	.,	
/SL/	14AA	Morgan, R.A. et al., "Human Gene Therapy", Annu. Rev. Biochem., Vol. 62, pp. 191-217 (1993)
	14AB	Morrison, S.J. et al., "Prospective Identification, Isolation by Flow Cytometry, and In Vivo Self-Renewal of Multipotent Mammalian Neural Crest Stem Cells", Cell, Vol. 96, pp. 737-749 (1999)
	14AC	Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies", Science, Vol. 229, pp. 1202-1207 (1985)
	14AD	Mulligan, R.C., "The Basic Science of Gene Therapy", Science, Vol. 260, pp. 926-932 (1993)
1.	14AE	Mulligan, R.C. et al., "Selection for animal cells that express the <i>Escherichia coli</i> gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA, Vol. 78, No. 4, pp. 2072 2076 (1981)
	14AF	Mullinax, R.L. et al., "Expression of a Heterodimeric Fab Antibody Protein in One Cloning Step", BioTechniques, Vol. 12, No. 6, pp. 864-869 (1992)
	14AG	Naramura, M. et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody–IL2 fusion protein against human melanoma cells", Immunology Letters, Vol. 39, pp. 91-99 (1994)
	14AH	Neuberger, M.S. et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function", Nature, Vol. 314, pp. 268-270 (1985)
	14AI	Nisonoff, A., "Idiotypes: Concepts and Applications", The Journal of Immunology, Vol. 147, No. 8, pp. 2429-2438 (1991)
	14AJ	Ohage, E. et al., "Intrabody Construction and Expression. I. The Critical Role of V _L Domain Stability", J. Mol. Biol., Vol. 291, pp. 1119-1128 (1999)
	14AK	Ohage, E.C. et al., "Intrabody Construction and Expression. II. A Synthetic Catalytic Fv Fragment", J. Mol. Biol., Vol. 291, pp. 1129-1134 (1999)
	14AL	O'Hare, K. et al., "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA, Vol. 78, No. 3, pp. 1527-1531 (1981)
	14AM	Oi, V.T. et al., "Chimeric Antibodies", BioTechniques, Vol. 4, No. 3, pp. 214-221 (1986)
$\overline{\mathbf{V}}$	14AN	Order, S.E., Chapter 15: "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", Monoclonal Antibodies for Cancer Detection and Therapy, Academic Press Inc., publ., Baldwin, R.W. et al., eds., pp. 303-316 (1985)
EXAM	INER	DATE CONSIDERED 11/06/2007

FORM PTO-1449 U.S. DE MENT OF COMMERCE (REV. 7-85) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

Sheet 15 of 33

OTHER DOCUMENTS: (Including Author, Title, Date, Pertinent pages, Etc.)

			, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
/SI	L	15AA	Padlan, E.A., "A Possible Procedure for Domains While Preserving Their Ligan 4/5, pp. 489-498 (1991)	or Reducing the Immunogenicity of Antibody Variable ad-Binding Properties", Molecular Immunology", Vol. 28, No.
		15AB	Patten, P.A. et al., "Applications of DN Opinion in Biotechnology, Vol. 8, pp. 7	A shuffling to pharmaceuticals and vaccines", Current 24-733 (1997)
1		15AC		system for the eukaryotic expression of antibodies or their lisplay libraries", Gene, Vol. 187, pp. 9-18 (1997)
1		15AD	Peterson, J.J. et al., "Enzymatic Cleav Bioconjugate Chemistry, Vol. 10, No. 4	age of Peptide-Linked Radiolabels from Immunoconjugates", 4, pp. 553-557 (1999)
1		15AE	Proba, K. et al., "Antibody scFv Fragm J. Mol. Biol., Vol. 275, pp. 245-253 (19	ents Without Disulfide Bonds Made by Molecular Evolution", 198)
		15AF		erence and termination between duplicated α-globin gene m for gene regulation", Nature, Vol. 322, pp. 562-565 (1986)
1		15AG	Riechmann, L. et al., "Reshaping hum (1988)	an antibodies for therapy", Nature, Vol. 332, pp. 323-327
		15AH	Riss, T.L. et al., "Comparison of MTT, proliferation and chemosensitivity assa	XTT, and a novel tetrazolium compound MTS for in vitro ays", Mol. Biol. Cell, Vol. 3 (Supp.), No. 1067, p. 184a (1992)
		15AI	Roguska, M.A. et al., "Humanization or resurfacing", Proc. Natl. Acad. Sci. US	f murine monoclonal antibodies through variable domain SA, Vol. 91, pp. 969-973 (1994)
		15AJ	Rondon, I.J. et al., "Intracellular Antibo Annu. Rev. Microbiol., Vol. 51, pp. 257	odies (Intrabodies) for Gene Therapy of Infectious Diseases", 7-283 (1997)
	•	15AK	Rüther, U. et al., "Easy identification of 1791-1794 (1983)	f cDNA clones", The EMBO Journal, Vol. 2, No. 10, pp.
		15AL	Sambrook, J. et al., Molecular Cloning Cold Spring Harbor Laboratory Press,	: A Laboratory Manual, Second Edition, Books 1, 2, and 3, publ., pp. xi-xxxviii (table of contents) (1989)
		15AM		rokaryotic genes for hygromycin B and G418 resistance as L cells", Gene, Vol. 30, pp. 147-156 (1984)
1	/	15AN	Sawai, H. et al., "Direct Production of Antibody Using Polymerase Chain Re Reproductive Immunology, Vol. 34, pp	the Fab Fragment Derived From the Sperm Immobilizing action and cDNA Expression Vectors", American Journal of p. 26-34 (1995)
E	KAMI	NER	/Sue Liu/	DATE CONSIDERED 11/06/2007

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

Sheet 16 of 33

D0185 US PCT APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. **FILING DATE**

ATTY. DOO

JULY 9, 2004

Group

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	
Schena, M. et al., "Quantitative Monito DNA Microarray", Science, Vol. 270, p	oring of Gene Expression Patterns with a Complementary p. 467-470 (1995)
	lymphoma outcome prediction by gene-expression profiling ture Medicine, Vol. 8, No. 1, pp. 68-74 (2002)
Shu, L. et al., "Secretion of a single-ge Natl. Acad. Sci. USA, Vol. 90, pp. 799	ene-encoded immunoglobulin from myeloma cells", Proc. 5-7999 (1993)
Skerra, A. et al., "Assembly of a Funct Science, Vol. 240, pp. 1038-1041 (198	ional Immunoglobulin F _v Fragment in <i>Escherichia coli</i> ', 88)
	Type 14:Human Immunodeficiency Virus Type 1 (HIV-1) V3 Library Induce Potent Neutralizing Antibody Responses bl. 72, No. 1, pp. 651-659 (1998)
Smith, A.D. et al., "Protein Engineering Human Rhinoviruses that Display Pep (1997)	g to Create Biologically Active Peptides: Recombinant tide Sequences", Behring Inst. Mitt., No. 98, pp. 229-239
Songsivilai, S. et al., "Bispecific antibo Immunol., Vol. 79, pp. 315-321 (1990)	dy: a tool for diagnosis and treatment of disease", Clin. Exp.
Sonneveld, P., "Multidrug resistance in Vol. 247, pp. 521-534 (2000)	n haematological malignancies", Journal of Internal Medicine,
	terns of breast carcinomas distinguish tumor subclasses with Sci., Vol. 98, No. 19, pp. 10869-10874 (2001)
	on of a highly efficient and versatile set of mammalian search, Vol. 17, No. 17, p. 7110 (1989)
Studnicka, G.M. et al., "Human-engine activity by preserving non-CDR compl No. 6, pp. 805-814 (1994)	eered monoclonal antibodies retain full specific binding ementarity-modulating residues", Protein Engineering, Vol. 7,
	React with Predetermined Sites on Proteins", Science, Vol.
Szybalska, E.H. et al., "Genetics of Hi of a Biochemical Trait", Proc. Natl. Ac	uman Cell Lines, IV. DNA-Mediated Heritable Transformation ad. Sci., Vol. 48, pp. 2026-2034 (1962)
Branched Artificial Proteins Using Uni	proaches to the Preparation of Peptide Dendrimers and protected Peptides as Building Blocks", Biomedical Peptides, 3, pp. 123-132 (1995)
/Sue Liu/	DATE CONSIDERED 11/06/2007
	DNA Microarray", Science, Vol. 270, p Shipp, M.A. et al., "Diffuse large B-cell and supervised machine learning", Na Shu, L. et al., "Secretion of a single-ge Natl. Acad. Sci. USA, Vol. 90, pp. 799. Skerra, A. et al., "Assembly of a Funct Science, Vol. 240, pp. 1038-1041 (198. Smith, A.D. et al., "Human Rhinovirus Loop Chimeras from a Combinatorial I against HIV-1", Journal of Virology, Vol. Smith, A.D. et al., "Protein Engineering Human Rhinoviruses that Display Pep (1997) Songsivilai, S. et al., "Bispecific antibo Immunol., Vol. 79, pp. 315-321 (1990) Sonneveld, P., "Multidrug resistance in Vol. 247, pp. 521-534 (2000) Sørlie, T. et al., "Gene expression pat clinical implications", Proc. Natl. Acad Stephens, P.E. et al., "The construction expression vectors", Nucleic Acids Re Studnicka, G.M. et al., "Human-engine activity by preserving non-CDR compl. No. 6, pp. 805-814 (1994) Sutcliffe, J.G. et al., "Antibodies That I 219, pp. 660-666 (1983) Szybalska, E.H. et al., "Genetics of Hi of a Biochemical Trait", Proc. Natl. Ac Tam, J.P. et al., "Chemoselective App Branched Artificial Proteins Using Un Proteins & Nucleic Acids, Vol. 1, No. 3

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE **INFORMATION DISCLOSURE CITATION**

Sheet 17 of 33

ATTY. DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. **FILING DATE** JULY 9, 2004

Group

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	17AA	Thorpe, P.E., "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological and Clinical Applications, Editrice Kurtis s.r.l., publ., Pinchera, A. et al., eds., pp. 475-506 (1985)
	17AB	Thorpe, P.E. et al., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates", Immunological Rev., Vol. 62, pp. 119-158 (1982)
	17AC	TIBTECH, Vol. 11, No. 5, pp. 155-215 (1993)
	17AD	Tolstoshev, P., "Gene Therapy, Concepts, Current Trials and Future Directions", Annu. Rev. Pharmacol. Toxicol., Vol. 32, pp. 573-596 (1993)
	17AE	Traunecker, A. et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes or HIV infected cells", The EMBO Journal, Vol. 10, No. 12, pp. 3655-3659 (1991)
	17AF	Traunecker, A. et al., "Janusin: New Molecular Design for Bispecific Reagents", Int. J. Cancer, Supp. 7, pp. 51-52 (1992)
	17AG	Traunecker, A. et al., "Soluble CD4 molecules neutralize human immunodeficiency virus type 1", Nature, Vol. 331, pp. 84-86 (1988)
	17AH	Tutt, A. et al., "Trispecific F(ab') ₃ Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells", The Journal of Immunology Vol. 147, No. 1, pp. 60-69 (1991)
:	17AI	Van Heeke, G. et al., "Expression of Human Asparagine Synthetase in <i>Escherichia coli</i> ", The Journal of Biological Chemistry, Vol. 264, No. 10, pp. 5503-5509 (1989)
	17AJ	van 't Veer, L.J. et al., "Gene expresion profiling predicts clinical outcome of breast cancer", Nature, Vol. 415, pp. 530-536 (2002)
	17AK	Vaughan, T.J. et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", Nature Biotechnology, Vol. 14, pp. 309-314 (1996)
	17AL	Vié, H. et al., "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 11337-11341 (1992)
	17AM	Wands, J.R. et al., "High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB ₈ Ag) Produced by Somatic Cell Hybrids", Gastroenterology, Vol. 80, No. 2, pp. 225-232 (1981)
\bigvee	17AN	West, M. et al., "Predicting the clinical status of human breast cancer by using gene expression profiles", Proc. Natl. Acad. Sci., Vol. 98, No. 20, pp. 11462-11467 (2001)
EXAMI	NER	/Sue Liu/ DATE CONSIDERED 11/06/2007

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOGNET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	• • • • • • • • • • • • • • • • • • • •
/SL/ 18AA	Wigler, M. et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell, Vol. 11, pp. 223-232 (1977)
18AB	Wilson, I.A. et al., "The Structure of an Antigenic Determinant in a Protein", Cell, Vol. 37, pp. 767-778 (1984)
18AC	Wirtz, P. et al., "Intrabody construction and expression III: Engineering hyperstable V _H domains", Protein Science, Vol. 8, pp. 2245-2250 (1999)
18AD	Wu, G.Y. et al., "Delivery Systems for gene therapy", Biotherapy, Vol. 3, pp. 87-95 (1991)
-18AE	Zhang, A. et al., "A Disulfide-Bound HIV-1 V3 Loop Sequence on the Surface of Human Rhinovirus 14 Induces Neutralizing Responses against HIV-1", Biol. Chem., Vol. 380, pp. 365-374 (1999)
18AF	Zheng, X.X. et al., "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide- Induced Septic Shock and Allogeneic Islet Transplantation", The Journal of Immunology, Vol. 154, pp. 5590-5600 (1995)
18AG	Zhu, Q. et al., "Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7", Journal of Immunological Methods, Vol. 231, pp. 207-222 (1999)
18AH	Zimmermann, J., "Refining the Toolbox for HTS", Genetic Engineering News, Vol. 20, No. 8, pp. 13, 40, 69 (April 15, 2000)
18AI	Zimmermann, K. et al., "A Triglycine Linker Improves Tumor Uptake and Biodistributions of 67-Cu- Labeled Anti-Neuroblastoma MAb chCE7 F(ab') ₂ Fragments", Nuclear Medicine & Biology, Vol. 26, pp. 943-950 (1999)
18AJ	Zurfluh, L.L. et al., "Auxin-induced changes in the patterns of protein synthesis in soybean hypocotyl", Proc. Natl. Acad. Sci. USA, Vol. 77, No. 1, pp. 357-361 (1980)
18AK	NCBI ENTREZ ACCESSION NO. gi AA418437, Hillier, L. et al., May 12, 1997
18AL	NCBI ENTREZ ACCESSION NO. gi AA595596, NCI-CGAP, September 12, 1997
18AM	NCBI ENTREZ ACCESSION NO. gi AA873266, NCI-CGAP, April 21, 1998
18AN	NCBI ENTREZ ACCESSION NO. gi AB000449, Nezu, J. et al., February 5, 1999
EXAMINER	/Sue Liu/ DATE CONSIDERED 11/06/2007

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE **INFORMATION DISCLOSURE CITATION**

Sheet 19 of 33

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. **FILING DATE** JULY 9, 2004

Group

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		(,,,,,,,	
/SL/	19AA	NCBI ENTREZ ACCESSION NO. gi AB006622, Ohara, O. et al., October 6, 2001	
	19AB	NCBI ENTREZ ACCESSION NO. gi AB006626, Ohara, O. et al., October 6, 2001	
	19AC	NCBI ENTREZ ACCESSION NO. gi AB007870, Ishikawa, K. et al., January 10, 2004	
	19AD	NCBI ENTREZ ACCESSION NO. gi AB007960, Seki, N. et al., August 13, 1998	
	19AE	NCBI ENTREZ ACCESSION NO. gi AB008515, Nakamura, M. et al., August 10, 2001	
	19AF	NCBI ENTREZ ACCESSION NO. gi AB009010, Kim, N. et al., July 26, 2001	
	19AG	NCBI ENTREZ ACCESSION NO. gi AB009282, Ishibashi, K., December 5, 1997	
	19AH	NCBI ENTREZ ACCESSION NO. gi[AB009426, Fujino, T. et al., April 14, 2000	
	19AI	NCBI ENTREZ ACCESSION NO. gi AB011114, Nagase, T. et al., July 5, 2002	
	19AJ	NCBI ENTREZ ACCESSION NO. gi AB011123, Nagase, T. et al., May 10, 2002	
	19AK	NCBI ENTREZ ACCESSION NO. gi[AB011535, Nakayama, M. et al., August 22, 1998	
	19AL	NCBI ENTREZ ACCESSION NO. gi AB014511, Ishikawa, K. et al., July 15, 1998	
	19AM	NCBI ENTREZ ACCESSION NO. gi AB014519, Ishikawa, K. et al., January 10, 2004	
\downarrow	19AN	NCBI ENTREZ ACCESSION NO. gi AB014520, Ishikawa, K. et al., February 6, 1999	
EXAM	INER	/Sue Liu/ DATE CONSIDERED 11/06/2007	

FORM PTO-1449
(REV. 7-85)
U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		<u> </u>
/SL/	20AA	NCBI ENTREZ ACCESSION NO. gi AB014529, Ishikawa, K. et al., May 10, 2002
	20AB	NCBI ENTREZ ACCESSION NO. gi AB014557, Ishikawa, K. et al., May 10, 2002
	20AC	NCBI ENTREZ ACCESSION NO. gijAB014558, Ishikawa, K. et al., February 6, 1999
	20AD	NCBI ENTREZ ACCESSION NO. gi AB014566, Ishikawa, K. et al., February 6, 1999
	20AE	NCBI ENTREZ ACCESSION NO. gi AB014585, Ishikawa, K. et al., January 10, 2004
	20AF	NCBI ENTREZ ACCESSION NO. gi AB018273, Nagase, T. et al., June 16, 1999
	20AG	NCBI ENTREZ ACCESSION NO. gilAB018306, Nagase, T. et al., January 10, 2004
	20AH	NCBI ENTREZ ACCESSION NO. gi AB018324, Nagase, T. et al., May 10, 2002
	20AI	NCBI ENTREZ ACCESSION NO. gi[AB020661, Nagase, T. et al., January 10, 2004
	20AJ	NCBI ENTREZ ACCESSION NO. gi AB023154, Nagase, T. et al., June 16, 1999
	20AK	NCBI ENTREZ ACCESSION NO. gi AB023194, Nagase, T. et al., January 10, 2004
	20AL	NCBI ENTREZ ACCESSION NO. gi AB026891, Sato, H. et al., February 10, 2001
	20AM	NCBI ENTREZ ACCESSION NO. gi[AB028957, Kikuno, R. et al., August 4, 1999
\/	20AN	NCBI ENTREZ ACCESSION NO. gi[AB029027, Kikuno, R. et al., January 10, 2004
EXAMI	NER	/Sue Liu/ DATE CONSIDERED 11/06/2007

FORM PTO-1449
U.S. DE MENT OF COMMERCE (REV. 7-85)
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, Etc.)

		•	
/SL/	21AA	NCBI ENTREZ ACCESSION NO. gi A	C004472, Lamerdin, J.E. et al., June 15, 2001
	21AB	NCBI ENTREZ ACCESSION NO. gi A	C005329, Lamerdin, J.E. et al., July 28, 1998
	21AC	NCBI ENTREZ ACCESSION NO. gi A	F000560, Jansa, P. et al., May 31, 1997
	21AD	NCBI ENTREZ ACCESSION NO. gi A	F000561, Jansa, P. et al., May 31, 1997
	21AE	NCBI ENTREZ ACCESSION NO. gi A	F003837, Oda, T. et al., September 6, 1997
	21AF	NCBI ENTREZ ACCESSION NO. gi A	F007155, Andersson, B. et al., June 9, 1998
	21AG	NCBI ENTREZ ACCESSION NO. gi A	F007156, Andersson, B. et al., June 9, 1998
	21AH	NCBI ENTREZ ACCESSION NO. gi A	F009674, Vasicek, T.J. et al., July 15, 1997
	21Al	NCBI ENTREZ ACCESSION NO. gijA	F029670, Doşanjh, M.K. et al., February 24, 1998
	21AJ	NCBI ENTREZ ACCESSION NO. gi A	F030335, Communi, D. et al., July 16, 2002
	21AK	NCBI ENTREZ ACCESSION NO. gi A	F031824, Halfon, S. et al., June 24, 1998
	21AL	NCBI ENTREZ ACCESSION NO. gi A	F035299, Andersson, B. et al., July 7, 2000
	21AM	NCBI ENTREZ ACCESSION NO. gil	F038172, Andersson, B. et al., January 22, 1998
$\sqrt{}$	21AN	NCBI ENTREZ ACCESSION NO. gi A	F041259, Collins, C. et al., July 22, 1998
EXAMI	NER	/Sue Liu/	DATE CONSIDERED 11/06/2007

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

22AA	NCBI ENTREZ ACCESSION NO. gijA	F045583, Nishina, P.M. et al., December 15, 1998
22AB	NCBI ENTREZ ACCESSION NO. gi A	F055009, Andersson, B. et al., April 2, 1998
22AC	NCBI ENTREZ ACCESSION NO. gi A	F061261, Du, G. et al., October 23, 1998
22AD	NCBI ENTREZ ACCESSION NO. gi A	F068744, Ding, H. et al., September 13, 2001
22AE	NCBI ENTREZ ACCESSION NO. gi A	F070530, Andersson, B. et al., August 5, 1998
22AF	NCBI ENTREZ ACCESSION NO. giļA	F072247, Hendrich, B. et al., August 16, 1999
22AG	NCBI ENTREZ ACCESSION NO. gi A	F093420, Raynes, D.A. et al., November 29, 1998
22AH	NCBI ENTREZ ACCESSION NO. giļA	F102265, Matthijs, G. et al., November 10, 1998
22AI	NCBI ENTREZ ACCESSION NO. gi A	F109134, Liu, J. et al., January 10, 1999
22AJ	NCBI ENTREZ ACCESSION NO. gi A	F155654, Li, Y. et al., May 2, 2000
22AK	NCBI ENTREZ ACCESSION NO. gi A	1038821, NCI-CGAP, June 30, 1998
22AL	NCBI ENTREZ ACCESSION NO. gi A	l659108, NCI-CGAP, May 7, 1999
22AM	NCBI ENTREZ ACCESSION NO. gi A	1761647, NCI-CGAP, June 24, 1999
22AN	NCBI ENTREZ ACCESSION NO. gi A	.l813532, NCI-CGAP, July 8, 1999
NER	/Sue Liu/	DATE CONSIDERED 11/06/2007
	22AB 22AC 22AD 22AE 22AF 22AG 22AH 22AI 22AJ 22AK 22AL 22AM	NCBI ENTREZ ACCESSION NO. gi A 22AC NCBI ENTREZ ACCESSION NO. gi A 22AC NCBI ENTREZ ACCESSION NO. gi A 22AE NCBI ENTREZ ACCESSION NO. gi A 22AF NCBI ENTREZ ACCESSION NO. gi A 22AF NCBI ENTREZ ACCESSION NO. gi A 22AH NCBI ENTREZ ACCESSION NO. gi A 22AH NCBI ENTREZ ACCESSION NO. gi A 22AI NCBI ENTREZ ACCESSION NO. gi A 22AI NCBI ENTREZ ACCESSION NO. gi A 22AI NCBI ENTREZ ACCESSION NO. gi A 22AK NCBI ENTREZ ACCESSION NO. gi A 22AK NCBI ENTREZ ACCESSION NO. gi A 22AK NCBI ENTREZ ACCESSION NO. gi A 22AM NCBI ENTREZ ACCESSION NO. gi A 22AN NCBI ENTREZ ACCESSION NO. gi A 22AN NCBI ENTREZ ACCESSION NO. gi A

FORM PTO-1449
(REV. 7-85)

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

			, , , , , , , , , , , , , , , , , , , ,	
/SL/	23AA	NCBI ENTREZ ACCESSION NO. gi AJ001685, Adamkiewicz, T.V. et al., September 4, 1998		
	23AB	NCBI ENTREZ ACCESSION	NO. gi AJ011736, Kedra, D. et al., January 7, 1999	
	23AC	NCBI ENTREZ ACCESSION	NO. gi AL031228, Tubby, B., September 26, 2001	
	23AD	NCBI ENTREZ ACCESSION	NO. gi AL035307, Rhodes, S., January 28, 1999	
	23AE	NCBI ENTREZ ACCESSION I	NO. gi AL043470, Bloecker, H. et al., July 8, 1999	
	23AF	NCBI ENTREZ ACCESSION I	NO. gi AL049365, Wambutt, R. et al., August 3, 2004	
	23AG	NCBI ENTREZ ACCESSION I	NO. gi AL050025, Wambutt, R. et al., August 3, 2004	
	23AH	NCBI ENTREZ ACCESSION I	NO. gi AL050065, Koehrer, K. et al., February 18, 2000	
	23AI	NCBI ENTREZ ACCESSION I	NO. gi AL050290, Ansorge, W. et al., February 18, 2000	
	23AJ	NCBI ENTREZ ACCESSION I	NO. gi AL050345, Collins, J.E. et al., May 26, 1999	
	23AK	NCBI ENTREZ ACCESSION I	NO. gi D12763, Tominaga, S. et al., January 23, 2003	
	23AL	NCBI ENTREZ ACCESSION	NO. gi D13413, Croyle, M.L. et al., February 14, 2003	
	23AM	NCBI ENTREZ ACCESSION	NO. gi D16815, Kamizono, A. et al., February 4, 1999	
$\sqrt{}$	23AN	NCBI ENTREZ ACCESSION	NO. gi D26158, Sakai, K. et al., July 6, 1999	
EXAMIN	ER	/Sue Liu/	DATE CONSIDERED	
		/Out Lid/	44/00/0007	

FORM PTO-1449
U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

24AM 24AN	NCBI ENTREZ ACCESSION NO. gi L07540, O'Donnell, M. et al., October 7, 1996 DATE CONSIDERED
24AM	
	NCBI ENTREZ ACCESSION NO. gi L07261, Joshi, R. et al., May 6, 1993
24AL	NCBI ENTREZ ACCESSION NO. gi K03498, Ono, M. et al., February 13, 1996
24AK	NCBI ENTREZ ACCESSION NO. gi J05581, Gendler, S.J. et al., January 7, 1995
24AJ	NCBI ENTREZ ACCESSION NO. gi J04599, Fisher, L.W. et al., June 11, 1993
24AI	NCBI ENTREZ ACCESSION NO. gi J04027, Verma, A.K. et al., August 19, 1995
24AH	NCBI ENTREZ ACCESSION NO. gi J00277, Tabin, C.J. et al., February 13, 2004
24AG .	NCBI ENTREZ ACCESSION NO. gi[D89377, limura, T. et al., September 4, 1999
24AF	NCBI ENTREZ ACCESSION NO. gi D87119, Ohno, I. et al., March 11, 1998
24AE	NCBI ENTREZ ACCESSION NO. gi D85131, Tsutsui, H. et al., February 1, 2003
24AD	NCBI ENTREZ ACCESSION NO. gi D83542, Shimoyama, Y. et al., October 30, 2000
24AC	NCBI ENTREZ ACCESSION NO. gi D67031, Katagiri, T. et al., December 10, 1997
24AB	NCBI ENTREZ ACCESSION NO. gi D63390, Adachi, H. et al., February 13, 1999
24AA	NCBI ENTREZ ACCESSION NO. gi D28118, Koyano-Nakagawa, N. et al., August 1, 2002
	24AB 24AC 24AD 24AE 24AF 24AG 24AH 24AI 24AJ 24AL

Sheet 25 of 33

FORM PTO-1449
(REV. 7-85)

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	25AA	NCBI ENTREZ ACCESSION NO. gi L10678, Honore, B. et al., October 14, 1993
	25AB	NCBI ENTREZ ACCESSION NO. gi L13463, Siderovski, D.P. et al., March 5, 1996
	25AC	NCBI ENTREZ ACCESSION NO. gi L13972, Chang, M.L. et al., July 12, 1995
	25AD	NCBI ENTREZ ACCESSION NO. gi L25665, Vernet, C. et al., May 16, 1995
	25AE	NCBI ENTREZ ACCESSION NO. gi L32976, Ing, Y.L. et al., January 7, 1995
	25AF	NCBI ENTREZ ACCESSION NO. gi L34059, Suzuki, S. et al., June 29, 1994
	25AG	NCBI ENTREZ ACCESSION NO. gi L37033, Lam, E. et al., May 16, 1996
1	25AH	NCBI ENTREZ ACCESSION NO. gi L40802, Labrie, Y. et al., October 13, 1995
	25 <u>A</u> I	NCBI ENTREZ ACCESSION NO. gi L43821, Law, S.F. et al., May 1, 1996
	25AJ	NCBI ENTREZ ACCESSION NO. gi M11717, Hunt, C. et al., November 8, 1994
	25AK	NCBI ENTREZ ACCESSION NO. gi M14333, Semba, K. et al., March 27, 1998
-	25AL	NCBI ENTREZ ACCESSION NO. gi M22489, Wozney, J.M. et al., October 31, 1994
-	25AM	NCBI ENTREZ ACCESSION NO. gi M23115, Lytton, J. et al., November 15, 1994
\downarrow	25AN	NCBI ENTREZ ACCESSION NO. gi M28668, Riordan, J.R. et al., April 27, 1993
▼ IMAX	I NER	DATE CONSIDERED

MENT OF COMMERCE U.S. DE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. **D0185 US PCT** APPLICATION NO.

10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

Sheet 26 of 33

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		NCBI ENTREZ ACCESSION NO. gi[M65066, Solberg, R. et al., November 10, 1994
	26AK	NCBI ENTREZ ACCESSION NO. gi M64788, Rubinfeld, B. et al., January 8, 1995
	26AJ	NCBI ENTREZ ACCESSION NO. gi M64571, West, R.R. et al., January 7, 1995
	26AI	NCBI ENTREZ ACCESSION NO. gi M64174, Wilks, A.F. et al., April 27, 1993
	26AH	NCBI ENTREZ ACCESSION NO. gi M60299, Ryan, M.C. et al., July 31, 1995
	26AG	NCBI ENTREZ ACCESSION NO. gi M58603, Meyer, R. et al., April 27, 1993
	26AF	NCBI ENTREZ ACCESSION NO. gi M57730, Holzman, L.B. et al., December 31, 1994
	26AE	NCBI ENTREZ ACCESSION NO. gi M36089, Thompson, L.H. et al., March 7, 1995
	26AD	
	26AC	NCBI ENTREZ ACCESSION NO. gi M34182, Beebe, S.J. et al., March 11, 1994
	2000	NCBI ENTREZ ACCESSION NO. gi M34064, Walsh, F.S. et al., November 17, 1993
	26AB	NCBI ENTREZ ACCESSION NO. gi M31682, Feng, Z.M. et al., January 6, 1995
ISLI .	26AA	NCBI ENTREZ ACCESSION NO. gi M29893, Polakis, P.G. et al., April 27, 1993

MENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. **FILING DATE** JULY 9, 2004

Group

Sheet 27 of 33

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

IMAXE	NER	DATE CONSIDERED				
$\sqrt{}$	27AN	NCBI ENTREZ ACCESSION NO. gi U15655, Mavrothalassitis, G.J., February 3, 1996				
	27AM	NCBI ENTREZ ACCESSION NO. gi U14971, Frigerio, J.M. et al., January 26, 1996				
NCBI ENTREZ ACCESSION NO. gi U09578, Sithanandam, G. et al., January 25, 199						
	27AK	NCBI ENTREZ ACCESSION NO. gi U03688, Sutter, T.R. et al., July 6, 1994				
	27AJ	NCBI ENTREZ ACCESSION NO. gi S70154, Song, X.Q. et al., September 23, 1994				
	27AI .	NCBI ENTREZ ACCESSION NO. gi S67070, Elisei, R. et al., February 5, 1994				
	27AH	NCBI ENTREZ ACCESSION NO. gi S37730, Binkert, C. et al., May 8, 1993				
	NCBI ENTREZ ACCESSION NO. gi NM_017432, Mittler, G. et al., August 21, 2004 27AG					
	27AF	NCBI ENTREZ ACCESSION NO. gi[NM_006979, Taylor, K.M. et al., August 20, 2004				
	27AE	NCBI ENTREZ ACCESSION NO. gi[NM_004713, Carbonnelle, D. et al., August 23, 2004				
	27AD	NCBI ENTREZ ACCESSION NO. gi M96684, Bergemann, A.D. et al., January 8, 1995				
	27AC	NCBI ENTREZ ACCESSION NO. gi M88458, Hsu, V.W. et al., April 27, 1993				
	27AB	NCBI ENTREZ ACCESSION NO. gi M87339, Chen, M. et al., October 7, 1996				
/SL/	27AA	NCBI ENTREZ ACCESSION NO. gi M80482, Kiefer, M.C. et al., January 7, 1995				
		· · · · · · · · · · · · · · · · · · ·				

Sheet 28 of 33

ATTY. DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. FILING DATE

JULY 9, 2004

Group

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	(,,,,,,,
/SL/ 28/	NCBI ENTREZ ACCESSION NO. gi U19718, Faraco, J. et al., October 26, 1995
28/	NCBI ENTREZ ACCESSION NO. gi U19775, Zervos, A.S. et al., December 29, 1995
28/	NCBI ENTREZ ACCESSION NO. gi U21551, Schuldiner, O. et al., September 20, 1996
28/	NCBI ENTREZ ACCESSION NO. gi U25138, Meera, P. et al., June 14, 1996
28/	NCBI ENTREZ ACCESSION NO. gi U34994, Hartley, K.O. et al., April 12, 2001
28/	NCBI ENTREZ ACCESSION NO. gi U37518, Wiley, S.R. et al., January 6, 1996
28/	NCBI ENTREZ ACCESSION NO. gi U41344, Grover, J. et al., June 3, 1998
28/	NCBI ENTREZ ACCESSION NO. gijU43368, Grimmond, S. et al., March 7, 1996
28/	NCBI ENTREZ ACCESSION NO. gi U47025, Gelinas, R.P. et al., January 31, 1996
28/	NCBI ENTREZ ACCESSION NO. gi U51166, Neddermann, P. et al., June 18, 1996
28	NCBI ENTREZ ACCESSION NO. gi U51903, Brill, S. et al., December 5, 1996
28	NCBI ENTREZ ACCESSION NO. gi U52840, Simmons, A.D. et al., April 2, 1998
28.	NCBI ENTREZ ACCESSION NO. gi U57057, Zaphiropoulos, P.G. et al., February 21, 1997
28.	NCBI ENTREZ ACCESSION NO. gi U57352, Garcia-Anoveros, J. et al., March 11, 1997 AN
EXAMINER	DATE CONSIDERED

EXAMINER

^{*}EXAMINER: Initial of reference and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

29AI	NCBI ENTREZ ACCESSION NO. gi U71364, Sun, J. et al., November 1, 1996			
29AI	NCBI ENTREZ ACCESSION NO. gi U72649, Rouault, J.P. et al., December 4, 1996			
29AI	NCBI ENTREZ ACCESSION NO. gi U79287, Andersson, B. et al., November 28, 2000			
29A	NCBI ENTREZ ACCESSION NO. gi U80040, Juang, H.H. et al., December 11, 1996			
29AI	NCBI ENTREZ ACCESSION NO. gi U81561, Jiang, S. et al., September 3, 1997			
29A	NCBI ENTREZ ACCESSION NO. gi U84570, Pruijn, G.J.M. et al., February 10, 1997			
29A	NCBI ENTREZ ACCESSION NO. gi U90902, Andersson, B. et al., March 29, 1997			
29A	NCBI ENTREZ ACCESSION NO. gi U93305, Fisher, S.E. et al., December 21, 1997			
29A	NCBI ENTREZ ACCESSION NO. gi U97067, Janssens, B. et al., November 10, 1999			
29A	NCBI ENTREZ ACCESSION NO. gi U97188, Mueller-Pillasch, F. et al., September 11, 1998			
29A	NCBI ENTREZ ACCESSION NO. gi W29065, Macke, J. et al., May 8, 1996			

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		·	
/SL/	30AA	NCBI ENTREZ ACCESSION NO. gijW	/26652, Macke, J. et al., May 8, 1996
	30AB	NCBI ENTREZ ACCESSION NO. gijW	772186, Hillier, L. et al., June 19, 1996
	30AC	NCBI ENTREZ ACCESSION NO. gi Xi	06272, Hortsch, M. et al., September 12, 1993
	30AD	NCBI ENTREZ ACCESSION NO. gi Xi	06745, Wong, S.W. et al., July 26, 1995
	30AE	NCBI ENTREZ ACCESSION NO. gi X	12534, Pizon, V. et al., September 12, 1993
	30AF	NCBI ENTREZ ACCESSION NO. gi X	12794, Miyajima, N. et al., June 25, 1997
	30AG	NCBI ENTREZ ACCESSION NO. gi X	13293, Nomura, N. et al., September 12, 1993
	30AH	NCBI ENTREZ ACCESSION NO. gi X	13916, Herz, J. et al., April 18, 1996
1	30AI	NCBI ENTREZ ACCESSION NO. gi X	60708, Misumi, Y. et al., November 16, 1993
	30AJ	NCBI ENTREZ ACCESSION NO. gijX	63629, Shimoyama, Y. et al., February 6, 1992
 	30AK	NCBI ENTREZ ACCESSION NO. gi X	66435, Russ, A.P. et al., September 12, 1993
,	30AL	NCBI ENTREZ ACCESSION NO. gi X	67325, Rasmussen, U.B. et al., December 3, 2000
	30AM	NCBI ENTREZ ACCESSION NO. gilX	.70040, Ronsin, C. et al., May 26, 1993
丁	30AN	NCBI ENTREZ ACCESSION NO. gijX	70340, Qian, J.F. et al., December 7, 1993
XAMII	NER	1	DATE CONSIDERED
			4.4.0.0.0.0.0.

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY, DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	31AA	NCBI ENTREZ ACCESSION NO. gi X74331, Stadlbauer, F. et al., September 9, 2004
	31AB	NCBI ENTREZ ACCESSION NO. gi X74837, Bause, E. et al., November 15, 1993
	31AC	NCBI ENTREZ ACCESSION NO. gi X76029, Austin, C. et al., October 5, 1995
	31AD ⁻	NCBI ENTREZ ACCESSION NO. gi X76104, Deiss, L.P. et al., April 20, 1997
	31AE	NCBI ENTREZ ACCESSION NO. gi[X77909, Albertella, M.R. et al., May 31, 1994
	31AF	NCBI ENTREZ ACCESSION NO. gi X78817, Tribioli, C. et al., May 7, 1996
	31AG	NCBI ENTREZ ACCESSION NO. gi X78992, Nie, X.F. et al., May 3, 1995
	31AH	NCBI ENTREZ ACCESSION NO. gi X79067, Barnard, R.C. et al., September 9, 2004
	31AI	NCBI ENTREZ ACCESSION NO. gi X80507, Sudol, M. et al., September 26, 1995
	31AJ	NCBI ENTREZ ACCESSION NO. gi X82207, Adams, M.D. et al., November 26, 1997
	31AK	NCBI ENTREZ ACCESSION NO. gi X84373, Cavailles, V. et al., August 9, 1995
	31AL	NCBI ENTREZ ACCESSION NO. gi X84740, Wei, Y.F. et al., February 16, 1996
	31AM	NCBI ENTREZ ACCESSION NO. gi X85545, Klink, A. et al., June 5, 1997
\downarrow	31AN	NCBI ENTREZ ACCESSION NO. gi X90392, Coy, J.F. et al., September 2, 1996
XAMII	NER	DATE CONSIDERED

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE MENT OF COMMERCE **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. **D0185 US PCT** APPLICATION NO. 10/501,035 **APPLICANT** HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

101.1	32AA	NCBI ENTREZ ACCESSION NO. gi X90976, Levanon, D. et al., November 25, 1998			
/SL/	02701				
	32AB	NCBI ENTREZ ACCESSION NO. gi X93209, Hospital, V. et al., November 25, 1997			
	32AC	NCBI ENTREZ ACCESSION NO. gi[XM_212189, International Human Genome Sequencing Consortium, January 3, 2003			
	32AD	NCBI ENTREZ ACCESSION NO. gi Y00971, lizasa, T. et al., September 12, 1993			
	32AE	NCBI ENTREZ ACCESSION NO. gi Y09846, Harun, R.B. et al., June 25, 1997			
	32AF	NCBI ENTREZ ACCESSION NO. gi[Y10032, Waldegger, S. et al., May 16, 1997			
	32AG	NCBI ENTREZ ACCESSION NO. gilY10055, Vanhaesebroeck, B. et al., October 2, 2003			
	32AH	NCBI ENTREZ ACCESSION NO. gilY11395, Mayer, H. et al., September 11, 2001			
	32AI	NCBI ENTREZ ACCESSION NO. gi Y12661, Canu, N. et al., July 3, 1997			
	32AJ	NCBI ENTREZ ACCESSION NO. gi Y12781, Bassi, M.T. et al., May 19, 1999			
	32AK	NCBI ENTREZ ACCESSION NO. gi Y15227, Liu, Y. et al., December 4, 1997			
	32AL	NCBI ENTREZ ACCESSION NO. gi Y15521, Ried, K. et al., January 20, 2003			
+	32AM	NCBI ENTREZ ACCESSION NO. gijY16241, Millevoi, S. et al., September 25, 1998			
\downarrow	32AN	NCBI ENTREZ ACCESSION NO. gi Y17711, Natter, S. et al., July 7, 1998			
EXAMI	NER	DATE CONSIDERED			

U.S. DE MENT OF COMMERCE PATENT AND TRADEMARK OFFICE


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DO SKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

/Sue Liu/

(the several sheets if necessary)

ATTY. DOCKET NO. D0185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. **FILING DATE** JULY 9, 2004

Group

U.S. PATENT DOCUMENTS **EXAMINER DOCUMENT NUMBER** CLASS SUBCLASS FILING DATE DATE NAME AB AC AD ΑE AF AG AH AI AJ ΑK FOREIGN PATENT DOCUMENTS TRANSLATION
YES NO DOCUMENT NUMBER **SUBCLASS** DATE OFFICE AM AN ХÓ AP AQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Ellis, et al., "Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line AR Transfected with an Antisense Expression Vector Specific for c-src", J Biol. Chem., Vol. 273(2), pp. 1052-1057 /SL/ (1998)AS **EXAMINER DATE CONSIDERED**

11/06/2007

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

. INFORMATION DISCLOSURE CITATION

Ris Eseveral sheets if necessary)

ATTY. DOCKET NO. DO185 US PCT APPLICATION NO. 10/501,035 APPLICANT HUANG ET AL. FILING DATE JULY 9, 2004

Group '

MAY 1 0 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA					1	
	Ab						
	AC						
,	AD						
	AE						
	AF				•		
	AG						
	AH						
	AI	. /					
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATI YES N	
/SL/	AM	WO99/64626	12/16/99	PCT				_
/SL/	AN	WO00/58520	10/5/00	PCT			0 0	
/SL/	AO	WO01/40517	6/7/01	PCT				
4	Z							
	4							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/SL/	AR	Porter, et al., "Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis", Oncogene, Vol. 16, pp. 1343-1352 (1998)				
	AS					
	AI					
EXAMINER /Sue Liu/			DATE CONSIDERED 11/06/2007			

SEP 0 6 2007

Substitute for form 1449/PTO

INFORMATION DISCLOSURED

STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet

1

PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COMPLETE IF KNOWN					
Application Number	10/501,035				
Filing Date	05/02/2005				
First Named Inventor	FEI HUANG				
Art Unit	1639				
Examiner Name	LIU, SUE XU				
Attorney Docket Number	D0185 US PCT				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
/SL/	A	Beck, et al., "BMP-induced growth suppression in colon cancer cells is mediated by p21 ^{WAF1} stabilization and modulated by RAS/ERK", Cellular Signalling, Vol. 19, pp. 1465-1472 (2007)	
. /SL/	AB	Wen, et al., "Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas", Oncogene, Vol. 25, pp. 2666-2673 (2006)	X
/SL/	AC	Hardwick, et al., "Bone Morphogenetic Protein 2 Is Expressed by, and Acts Upon, Mature Epithelial Cells in the Colon", Gastroenterology, Vol. 126, pp. 111-121 (2004)	
			·
	į		

·			PTO/SB/08B (8/03) use through 07/31/2006. OMB 0651-0031 ice; U.S. DEPARTMENT OF COMMERCE	
Substitute for form 1449/PTO		COMPLETE IF KNOWN		
		Application Number	10/501035	
INFORMATION D	ISCI OSLIRE	Filing Date	01/17/2003	
		First Named Inventor	FEI HUANG	
STATEMENT BY	APPLICANT(S)	Art Unit	1639	
(use as many sheets	as necessary)	Examiner Name	LIU, SUE XU	
Sheet 1	of 1 .	Attorney Docket Number	D0185 US PCT	

_ 		·		┪
		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if Englis language Translation is attached	h n
/SL/	AA	Sixth Annual Conference – Targeted Therapies in the Treatment of Breast Cancer, July 2003; "Development of Src Kinase Inhibitors for the Treatment of Breast Cancer", Arthur P. DeCillis, Group Director, Oncology Clinical Development, Bristol-Myers Squibb Oncology		
				!
			<u> </u>	
			-A	
	·		-/·\ -	_
			-/-	
			1	
	 			<u> </u>

ſ	Examiner	10 11 1	Date	11/06/2007
1	Signature	/Sue Liu/	Considered	11/06/2007